Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Principles and general themes
-
1. Oncolytic viruses: strategies, applications and challenges
- Dr. Stephen J. Russell
-
2. Directed evolution of AAV delivery systems for clinical gene therapy
- Prof. David Schaffer
-
6. The host response: adaptive immune response to viral vector delivery
- Prof. Roland W. Herzog
-
7. Gene therapy and virotherapy in the treatment of cancer
- Prof. Leonard Seymour
-
8. Gene therapy for the muscular dystrophies
- Prof. Jeff Chamberlain
- Major gene transfer platforms and gene therapy strategies
-
9. Gammaretroviral vectors: biology, design and applications
- Prof. Axel Schambach
-
13. Surface-mediated targeting of lentiviral vectors
- Prof. Dr. Christian Buchholz
-
14. Gene transfer and gene therapy
- Dr. David A. Williams
-
15. Tracking vector insertion sites to explore the biology of transduced cells in vivo
- Prof. Dr. Christof Von Kalle
-
16. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
17. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
20. Gene therapy for hemophilia
- Prof. Katherine High
- New technologies for sequence-specific editing of gene expression
-
21. Helper-dependent adenoviral vectors for gene therapy
- Prof. Nicola Brunetti-Pierri
-
22. HSV vectors: approaches to the treatment of chronic pain
- Prof. Joseph C. Glorioso
- Archived Lectures *These may not cover the latest advances in the field
-
23. RNAi for neurological diseases
- Prof. Beverly L. Davidson
-
24. Directed evolution of novel adeno-associated viral vectors for gene therapy
- Prof. David Schaffer
Printable Handouts
Navigable Slide Index
- Introduction
- Clonal marking by integrating vectors
- Integration site analysis by LAM-PCR
- Clonal distribution in available clinical trials
- Hematopoiesis in ADA-SCID gene therapy
- LMO2-activation in SCID-X1 gene therapy
- Clinical improvement in the CGD trial
- Insertional activation in CGD gene therapy
- Avoiding oncogenesis in gene therapy
- Wiskott-Aldrich Syndrome (WAS)
- Adverse events in gene therapy for X-WAS (T-ALL)
- Adverse events in gene therapy for X-WAS (AML)
- Characterization & understanding of pathogenesis
- Integrations in known proto-oncogenes
- No clonal dominance before T-ALL development
- AML: slow increase of the dominant clone
- Development of AML triggered by MDS1 clone
- MN1 as a possible trigger of AML development
- Safer vector systems & new technologies
- IS-profile of lentiviral SIN-vectors potentially safer
- Influence of vector type on clinical outcome
- SIN- RV revealed safer IS profile (testing's for CGD)
- LV integration site analysis: X-ALD trial
- Stable polyclonal hematopoietic repopulation
- Heterogenic repopulation of hematopoietic system
- Similar integration profile in ALD patients
- Top CIS are shared in ALD patients
- Targeted genome modification: nucleases (1)
- Targeted genome modification: nucleases (2)
- Specificity of DNA modification by ZFN
- Off-target DSB induction by ZFN
- The TALEN nuclease and how it performs
- Conclusions and outlook
- Acknowledgements
- Thank you
Topics Covered
- Clonal marking by integrating vectors
- Integration site analysis by LAM-PCR
- Analysis of gene therapy clinical trials for X-SCID, X-CGD, ADA-SCID & Cancer
- Avoiding oncogenesis in gene therapy
- Gene therapy for Wiskott-Aldrich Syndrome (WAS)
- Characterization & understanding of pathogenesis
- Integrations in known proto-oncogenes
- Possible triggers of AML development
- Safer vector systems & new technologies
- Lentiviral SIN-vectors
- Influence of vector type on clinical outcome
- LV integration site analysis: X-ALD trial
- Repopulation of hematopoietic system
- Targeted genome modification: nucleases
- Specificity of DNA modification by ZFN
- The TALEN nuclease and how it performs
Talk Citation
Von Kalle, C. (2014, September 3). Tracking vector insertion sites to explore the biology of transduced cells in vivo [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/OUWX8608.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Christof Von Kalle has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Tracking vector insertion sites to explore the biology of transduced cells in vivo
Published on September 3, 2014
35 min
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Christof von Kalle
from the National Center for Tumor
Diseases in Heidelberg in the
German Cancer Research Center.
I'm going to be talking about
tracking vector insertion sites
to explore the biology of
transduced cells in vivo.
0:16
Integrating vectors have been
used for a number of years
for the genetic
modification of cells.
This has been particularly
done extensively
in that formation, hematopoiesis.
Integrating vectors
have the properties
to place a copy of the
profile DNA somewhere
in the genome of
the transfused sell.
This integration occurs
depending on the vector system
in a semi-random
fashion and is stable.
You can see that a marking that
occurs in a progenitor or a stem
cell is actually then passed
on to the progeny of that cell,
meaning that sampling of the
peripheral blood and analysis
for the integration sites
can delineate the activity
of progenitor and stem cells
in terms of their contribution
to different blood
lineages, the numbers
or cells, and their
activity over time.
1:17
The next slide shows the
possibility to analyze
such insertions in
very complex mixtures.
Usually if the blood formation
of an animal or a patient
is marked in part by retro
viral or anti-viral vectors,
the analytes that you need to find
this composition in a very complex
majority of cells may
not be transfused.
The number of cells or a cell
clones that carry a genetic vector
may be very large, and so in terms
of the analyte to be analyzed,
this can be very complex mixtures.
So a number of years ago,
we have revised methodology
that uses the unique
abilities of polymerases
to create transcripts of
such insertional events.
We used linear PCR
going from one primer
out into the genome to create
a high number of copies
of every insertional events in the
given sample or analyte which gives
us the opportunity to
then enrich these and go
through different steps
of enrichment, ligation,
and amplification without
losing at least all
of the copies of a given event.
So that the integration site
analysis that we then can perform
is very sensitive for the
presence of each individual event
just by the very fact that we have
been able to create multiple copies
of each individual event
at the very beginning
of the steps of this method.
The restriction length polymorphism
that is created by a such reaction
shows multiple bands, so one can
see multiple, amplified fragments
of different size indicating
that LTR insertion
loci with different DNA lengths
have been amplified by this method.
Hide